Information Provided By: 
Fly News Breaks for July 31, 2018
TNDM
Jul 31, 2018 | 05:20 EDT
Piper Jaffray analyst JP McKim raised his price target for Tandem Diabetes to $32 saying the company last night reported "strong" Q2 results with pump shipments and sales beating expectations. He believes the company is "remaining conservative and thoughtful for the remainder of the year" with its guidance. Underlying business post the Basal-IQ approval has accelerated off of levels seen in Q2, McKim tells investors in a research note. He keeps an Overweight rating on Tandem Diabetes.
News For TNDM From the Last 2 Days
